Goldman Raises HCA Healthcare Price Target to $558 After Solid Q4 Results and Confident 2026 Guidance
Goldman Sachs increased its HCA Healthcare price target to $558 and kept a Buy rating after the company beat fourth-quarter 2025 EBITDA expectations and issued 2026 EBITDA guidance above consensus. HCA reported stronger-than-expected margins and EPS, outlined resiliency-driven cost savings and plans for higher capital spending alongside a new $10 b…